Acyl‐ghrelin‐mediated pathways can improve body weight regulation, metabolism, and the anabolic and neuroprotective actions of growth hormone and IGF‐1, and have been considered promising therapeutic targets in ALS.[34] Acyl‐ghrelin has a short half‐life (≈9–13 min in human plasma) due to rapid degradation by esterases such as BuChE in circulation.[12, 13] Due to its peptidic nature, it undergoes first pass metabolism in the liver and rapid renal elimination. The gene discussed is IGF1; the disease is amyotrophic lateral sclerosis.